A case report and discussion of cetuximab-induced folliculitis.
Use of human epidermal growth factor receptor inhibitors by oncologists has led to the occurrence of an acne-like eruption that is technically a folliculitis. Misidentification of the rash often leads to unfruitful treatment attempts as its morphologic features do not correlate well with its histologic findings. We describe a case history, diagnosis, and management of a man undergoing treatment with cetuximab for colorectal carcinoma who experienced the characteristic follicular eruption. Our patient responded well to daily moisturizers and 1% clindamycin gel and experienced near complete resolution of the rash. The evolving research and understanding of this unique entity are also discussed.
Adams
Derrick H
DH
David Grant Medical Center, Travis Air Force Base, California, USA. derrick.adams@travis.af.mil
Nutt
Terri
T
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D002981:Clindamycin / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005499:Folliculitis / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D012074:Remission Induction
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002981:Clindamycin; D000077146:Irinotecan; D066246:ErbB Receptors; D000068818:Cetuximab; D002166:Camptothecin